PTEN and urogenital neoplasm: Crossing PB-Cre4; SypELDTA transgenic mice with Pten knockout mice [41], [54] or other established mouse prostate cancer models with preferential NE differentiation, such as TRAMP or LADY [55], [56], should decisively determine the role of NE cells in prostate carcinogenesis.